CLINICAL_TRIALS
trial_result
· 2017-01-19
Clinical Trial Update: Arimoclomol in Sporadic Inclusion Body Myositis [Phase 2, Phase 3]
Summary
This document reports an update on a Phase 2/3 trial of arimoclomol for sporadic Inclusion Body Myositis, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Richard Barohn, MD | Conditions: Inclusion Body Myositis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-01-19